Docetaxel

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Docetaxel

Examples of brand names: Taxotere [EU/DE]

ATC code: L01CD02

Main use (for orientation): Selected cancers

Documented research summary

Cannabis tea without a significant clinical change in docetaxel pharmacokinetics (EX06); separate cell/xenograft combinations with CBD/extracts are not clinical synergy.

Uncertainties and limitations

Intravenous docetaxel BEIZRAY, formulation-specific US SPL; the clinical tea experiment is a different product/setting.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

4 separately recorded findings. Each statement applies to its documented study context.

Cannabis tea (multi-substance preparation) – clinically investigated

Finding ID: B0096

Type of result: Context-specific finding; read the limitations

Observation: No significant effect on systemic pharmacokinetics with the tea preparation investigated.

Mechanism: CYP3A/pharmacokinetic interaction clinically assessed

Study type: Clinical pharmacokinetic study with consecutive treatment cycles

Context studied: Clinical comparison across cycles.

Clinical interpretation: Individual medical / pharmaceutical assessment; do not use as dosage instructions

Limitations and uncertainties: No general conclusion about anticancer efficacy or single-ingredient CBD/THC preparations.

Original sources for this finding: Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel [EX06]

CBD – laboratory and animal studies

Finding ID: B0200

Type of result: Preclinical evidence

Observation: CBD plus docetaxel showed model/molar-ratio-dependent synergy in MCF7.

Mechanism: Cytotoxic synergy

Study type: Cell / animal experiment, abstract read

Context studied: Synergy models partly contradictory; ratio 636:1 cannot be extrapolated clinically.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: No human drug–drug interaction; not a treatment recommendation.

Original sources for this finding: Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms. [BMED34576262]

CBD-rich cannabis extract – laboratory and animal studies

Finding ID: B0201

Type of result: Preclinical evidence

Observation: CBD-BDS enhanced docetaxel effects in prostate-cancer xenografts.

Mechanism: Antitumour effect

Study type: Cell / animal experiment, abstract read

Context studied: Extract administered intraperitoneally; not a single-ingredient isolated CBD preparation.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: No human drug–drug interaction; not a treatment recommendation.

Original sources for this finding: Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. [BMED22594963]

Cannabis extract PHEC-66 – laboratory and animal studies

Finding ID: B0202

Type of result: Preclinical evidence

Observation: Nuanced, potentially additive effect with docetaxel.

Mechanism: Cell viability

Study type: Cell / animal experiment, abstract read

Context studied: Melanoma cell lines; the title's use of synergistic is stronger than the cautious abstract results.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: No human drug–drug interaction; not a treatment recommendation.

Original sources for this finding: Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells. [BMED41751930]

References and access status

[V2_LABEL_D0404] BEIZRAY (DOCETAXEL) INJECTION, SOLUTION [ZHUHAI BEIHAI BIOTECH CO., LTD.]

Original source / bibliographic reference

Authors: Zhuhai Beihai Biotech Co., Ltd.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[EX06] Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel

Original source / bibliographic reference

Authors: Engels FK; de Jong FA; Sparreboom A; Mathôt RAA; Loos WJ; Kitzen J; de Bruijn P; Verweij J; Mathijssen RHJ

Year: 2007

Source type: Clinical pharmacokinetic study with consecutive treatment cycles

DOI: 10.1634/theoncologist.12-3-291

PMID: 17405893

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED41751930] Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.

Original source / bibliographic reference

Authors: Bachari A, Telukutla S, Nazar N, Piva TJ, Mantri N.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.3390/ijms27041794

PMID: 41751930

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED34576262] Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.

Original source / bibliographic reference

Authors: Alsherbiny MA, Bhuyan DJ, Low MN, Chang D, Li CG.

Year: 2021

Source type: Publication; title and abstract reviewed

DOI: 10.3390/ijms221810103

PMID: 34576262

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED22594963] Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Original source / bibliographic reference

Authors: De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V.

Year: 2013

Source type: Publication; title and abstract reviewed

DOI: 10.1111/j.1476-5381.2012.02027.x

PMID: 22594963

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility